Amneal submits a BLA for a new Xolair biosimilar, promising affordable treatment options for asthma and allergies, enhancing patient access and competition. Food allergies and CSU, which involve hives and swelling, further highlight the broad demand for effective biologic therapies. The Xolair biosimilar space is still new. In March 2025, the FDA approved Omlyclo (omalizumab-igec), developed by South Korea–based Celltrion, as the first interchangeable biosimilar to Xolair. If approved, Amneal’s biosimilar would become another U.S.-marketed alternative to Xolair, alongside its competitor Omlyclo.